文献速递慢阻肺

Cytisinicline用于自报COPD吸烟者的戒烟疗效:ORCA-2与ORCA-3试验的事后分析

Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials.
PubMed 文献 · Thorax · 2026-01-15

本研究基于ORCA-2和ORCA-3两项3期双盲安慰剂对照试验的事后分析,纳入1602名吸烟者(其中145名自报COPD),评估Cytisinicline(3mg每日三次,6或12周)联合行为支持的戒烟疗效。结果显示,在COPD和非COPD亚组中,Cytisinicline均显著提高生化验证的持续戒烟率,且耐受性良好,无严重治疗相关事件。

要点

  • Cytisinicline在自报COPD吸烟者中显著提高戒烟率,6周组17.3% vs 2.1%,12周组19.1% vs 4.3%。
  • 非COPD亚组同样获益,6周组19.3% vs 5.5%,12周组32.6% vs 8.6%。
  • Cytisinicline耐受性良好,未报告严重治疗相关事件。

核心结论

  • Cytisinicline显著提高自报COPD和非COPD吸烟者的戒烟率,且耐受性良好,支持其作为COPD吸烟者戒烟的可行治疗选择。

研究设计与样本

  • 基于ORCA-2和ORCA-3两项3期双盲安慰剂对照试验的事后分析,共纳入1602名参与者,其中145名(9.3%)自报COPD。
  • 参与者接受6或12周Cytisinicline(3mg每日三次)或安慰剂(12周),并联合行为支持。

主要发现

  • COPD参与者年龄更大、吸烟史更长、尼古丁依赖程度更高。
  • Cytisinicline在COPD和非COPD亚组中均与显著更高的戒烟率相关,且治疗效应无统计学异质性。
  • 6周组COPD戒烟率17.3% vs 安慰剂2.1%(OR 9.7,p=0.03),非COPD 19.3% vs 5.5%(OR 4.1,p<0.0001)。
  • 12周组COPD戒烟率19.1% vs 安慰剂4.3%(OR 5.3,p=0.04),非COPD 32.6% vs 8.6%(OR 5.2,p<0.0001)。

关键数值与推荐

  • 主要结局为治疗最后4周内生化验证的持续戒烟。
  • Cytisinicline剂量为3mg每日三次,疗程6或12周,联合行为支持。

临床怎么用

  • 对于自报COPD且希望戒烟的吸烟者,可考虑使用Cytisinicline(3mg每日三次,6或12周)联合行为支持。
  • 治疗期间未报告严重治疗相关事件,耐受性良好。

局限性

  • COPD为自报而非临床确诊,可能影响亚组准确性。
  • 事后分析设计,样本中COPD患者比例较小(9.3%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Quitting smoking is essential for stabilising and improving respiratory function in people with chronic obstructive pulmonary disease (COPD). OBJECTIVE: To evaluate the efficacy and safety of cytisinicline versus placebo for cessation among smokers with and without COPD. METHODS: This post hoc analysis used combined data from the phase 3 ORCA-2 (Ongoing Research of Cytisinicline for Addiction) and ORCA-3 double-blind, placebo-controlled trials. Participants received 6 or 12 weeks of cytisinicline or placebo. Of 1602 participants, 145 (9.3%) self-reported COPD. INTERVENTIONS: Participants received 3 mg of cytisinicline three times daily (6 weeks: n=532; 12 weeks: n=534) or placebo (12 weeks: n=536), plus behavioural support. OUTCOME: Biochemically verified continuous smoking abstinence during the last 4 treatment weeks. RESULTS: COPD participants were older, smoked longer and had greater nicotine dependence. Cytisinicline was associated with significantly higher smoking abstinence compared with placebo in both COPD and non-COPD subgroups. There was no statistical evidence of heterogeneity in treatment effect between arms. In the 6-week arm, quit estimates were 17.3% versus 2.1% (OR 9.7, p=0.03) for COPD and 19.3% versus 5.5% (OR 4.1, p<0.0001) for non-COPD. In the 12-week arm, quit estimates were 19.1% versus 4.3% (OR 5.3, p=0.04) for COPD and 32.6% versus 8.6% (OR 5.2, p<0.0001) for non-COPD. Cytisinicline was well tolerated with no serious treatment-related events. CONCLUSION: Cytisinicline significantly increased quitting for smokers with and without COPD and was well tolerated. The findings support cytisinicline as a viable treatment for smokers with COPD who want to quit. TRIAL REGISTRATION NUMBER: ORCA-2 (NCT04576949) and ORCA-3 (NCT05206370).

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Prochaska J, Rubinstein M, Perdok R, et al. Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials. Thorax. 2026. PMID: 40962497. doi:10.1136/thorax-2025-223880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。